Abstracts tagged "juvenile dermatomyositis"

Abstract Number: 480 • 2018 ACR/ARHP Annual Meeting
Analyze Myositis with Ultrasound and Exercise (AMUSE) Kids- Initial Analysis of Longitudinal Data
Laura Tasan¹, Emily Brunner², Judy Squires³, Rohit Aggarwal⁴, Chester V. Oddis⁴, Christina K. Zigler⁵, Kaila Schollaert-Fitch⁶, Emily Mirizio⁷ and Kathryn S. Torok², ¹Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Radiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁶Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁷Peds Rheum, University of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: There is an unmet need for more objective disease outcome measures in Juvenile Myositis (JM) patients. This pilot study sought to test the reliability,…
Abstract Number: 481 • 2018 ACR/ARHP Annual Meeting
Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis
Emily Brunner¹, Laura Tasan², Kathryn S. Torok³, Bonny Rockette-Wagner⁴, Christina K. Zigler⁵, Kaila Schollaert-Fitch³, Diane Koontz⁶, Chester V. Oddis⁷ and Rohit Aggarwal⁸, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, ⁶Internal Medicine Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, Department of Medicine, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: The use of physical activity monitors (PAM), which objectively quantify free-living movement, may enhance assessment of disease activity in juvenile myositis (JM) clinical trials…
Abstract Number: 1332 • 2018 ACR/ARHP Annual Meeting
Proteomic Discovery Analysis Identifies Unique Proteins and Pathways Correlating with Different Clinical Activity and Damage Measures in Juvenile Dermatomyositis (JDM)
Hanna Kim¹, Angelique Biancotto², Foo Cheung², Terrance P. O'Hanlon³, Yan Huang⁴, Frederick W. Miller³, Raphaela Goldbach-Mansky⁴ and Lisa G. Rider⁵, ¹Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ²Center for Human Immunology Autoimmunity and Inflammation (CHI), NIAID, NIH, Bethesda, MD, ³Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁴Translational Autoinflammatory Disease Section (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁵Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD
Background/Purpose: JDM is a complex heterogeneous autoimmune disease. To define biomarkers and better understand JDM pathogenesis, aptamer-based proteomic technology was used to mine the serum…
Abstract Number: 1347 • 2018 ACR/ARHP Annual Meeting
A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies
Sara Faghihi-Kashani¹, Lisa G. Rider², David Bluemke³, Ashkan Malayeri⁴, Evrim Turkbey⁴, Joseph Shrader⁵, John McGrath⁶, Elizabeth Jones⁷, Jamie Marco⁸, Frederick W. Miller⁹ and Adam Schiffenbauer¹⁰, ¹Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁵Rehabilitation Medicine, National Institutes of Health, Bethesda, MD, ⁶Social and Scientific Systems, Inc., Durham, NC, ⁷Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD, ⁸Radiology and Imaging Sciences National Institutes of Health, Bethesda, MD, ⁹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ¹⁰NIEHS, NIH, Bethesda, MD
Background/Purpose: There is a lack of standardized methodology for assessing whole body MRI (WBMRI) in idiopathic inflammatory myopathy (IIM) patients. This leads to difficulty in…
Abstract Number: 1402 • 2018 ACR/ARHP Annual Meeting
The Relationship of Pain, Fatigue and Emotional Distress with Quality of Life in Juvenile Myositis
Kyle J. Fahey¹, Elizabeth L. Gray², Rowland W. Chang³, David Cella⁴, Lauren M. Pachman⁵ and Kaveh Ardalan⁶, ¹Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Preventive Medicine, Medicine, and Physical Medicine & Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Departments of Medical Social Sciences, Neurology, Pediatrics, Preventive Medicine, and Psychiatry and Behavioral Sciences,, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁶Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile Myositis (JM) is an autoimmune disease that negatively impacts quality of life (QoL) outcomes via muscle weakness and vasculopathic rashes. The relative contribution…
Abstract Number: 1279 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Achieving a Drug-Free Remission in Patients with Juvenile Dermatomyositis
Tomokazu Nagakura¹, Takuma Ito², Masateru Kusuda², Tuyoshi Yamatou², Tomohiro Kubota², Yuuichi Yamasaki², Yukiko Nonaka², Tomoko Takezaki², Harumi Akaike³, Yasuhito Nerome², Hiroyuki Imanaka² and Syuji Takei⁴, ¹Pediatrics, The Holy Mother of Grace Hospital Home for Children and Persons with Severe Motor and Intellectual Disabilities, Usuki, Japan, Usuki, Japan, ²Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, ³Department of Pediatrics, Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, ⁴Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshma, Japan
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children. Approximately one-third of JDM patients attain drug-free remission (DFR) without relapse; however,…
Abstract Number: 2137 • 2017 ACR/ARHP Annual Meeting
Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients
Vladislav Tsaltskan¹, Annette Aldous², Sam Serafi¹, Heidi Sami¹, Gulnara Mamyrova¹, Frederick W Miller³, Sam Simmens², Rodolfo Curiel¹, Olcay Y. Jones⁴ and Lisa G Rider³, ¹Department of Rheumatology, George Washington University, Washington, DC, ²Department of Epidemiology and Biostatistics, George Washington University Milken Institute School of Public Health, Washington, DC, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Juvenile idiopathic inflammatory myopathies (JIIM) are rare, autoimmune chronic muscle diseases of childhood with significant potential long-term morbidity. In this study we investigate associations…
Abstract Number: 2142 • 2017 ACR/ARHP Annual Meeting
Autoantibodies Recognizing Cytosolic 5’-Nucleotidase 1A Are Associated with More Severe Disease in Patients with Juvenile Myositis
Richard Yeker¹, Iago Pinal-Fernandez², Takayuki Kishi³, Ira N. Targoff⁴, Frederick W Miller³, Lisa G Rider³ and Andrew Mammen⁵, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD
Background/Purpose: Autoantibodies recognizing cytosolic 5’-nucleotidase 1A (NT5C1A) are present in the sera of adults with myositis and other autoimmune diseases. They are especially prevalent in…
Abstract Number: 2259 • 2017 ACR/ARHP Annual Meeting
Quality of Life Evaluation in New Onset Juvenile Dermatomyositis Patients from the Printo Trial
Andressa Guariento¹, Gabriella Giancane², Elena Fueri¹, Francesco Zulian³, Angelo Ravelli⁴, Bo Magnusson³, Tadej Avcin³, Fabrizia Corona³, Valeria Gerloni¹, Claudia Bracaglia¹, Rolando Cimaz¹, Antonella Meini², Silvana Martino³, Anne Pagnier¹, Michel Rodiere³, Christine Soler³, Valda Stanevicha³, Rebecca ten Cate⁵, Jelena Vojinovic³, Simona Angioloni¹, Luca Villa¹, Michele Pesce¹, Irene Gregorini¹, Chiara Pallotti¹, Alberto Martini⁶, Angela Pistorio³ and Nicola Ruperto³, ¹Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ²Pediatria II, Reumatologia - PRINTO, Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ³Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ⁴University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁵Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common clinical pediatric idiopathic inflammatory myopathy and it may severely compromise the quality of life of affected patients.…
Abstract Number: 2336 • 2017 ACR/ARHP Annual Meeting
Expression of Myxovirus-Resistance Protein a: A Possible Marker of Muscular Disease Activity in Juvenile Dermatomyositis
Sirisucha Soponkanaporn¹, Claire Deakin², Lucy Marshall², Cerise Johnson², Peter Schutz¹ and Lucy R Wedderburn², ¹Infection Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, ²Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic autoimmune myopathy characterized by proximal muscle weakness and typical skin rashes. Type I interferon (IFN) gene expression in…
Abstract Number: 2337 • 2017 ACR/ARHP Annual Meeting
Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) and Myositis Autoantibody Groups
Hanna Kim¹, Angélique Biancotto², Foo Cheung³, Terrance P. O'Hanlon⁴, Ira N. Targoff⁵, Yan Huang⁶, Frederick W Miller⁴, Raphaela Goldbach-Mansky⁶ and Lisa G Rider⁴, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ³Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease. Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
Abstract Number: 2342 • 2017 ACR/ARHP Annual Meeting
Transcriptomic Analysis Reveals Mitochondrial and Monocyte Dysfunctions Are Linked to the Interferonopathy of Juvenile Dermatomyositis
Claire Deakin¹, Elizabeth Rosser¹, Lucy Marshall¹, Meredyth Wilkinson², Aziza Khabbush³, Stefania Simou¹, Georg Otto³, Stefanie Dowle³, Daniel Kelberman³, Simon Yona², Simon Eaton³ and Lucy R Wedderburn¹, ¹Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, ²Division of Medicine, University College London, London, United Kingdom, ³Genetics and Genomic Medicine Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom
Background/Purpose: Although type I interferon (IFN1) and endoplasmic reticulum (ER) stress have been implicated in pathogenesis of juvenile dermatomyositis (JDM), little else is known about…
Abstract Number: 2895 • 2017 ACR/ARHP Annual Meeting
Predictors of Hospitalization, Length of Stay and Costs of Care Among Children with Juvenile Dermatomyositis in the United States
Michael C. Kwa¹, Jonathan I. Silverberg² and Kaveh Ardalan^3,4, ¹Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disease that causes significant morbidity and quality of life impairment. Little is known about JDM inpatient burden…
Abstract Number: 2960 • 2017 ACR/ARHP Annual Meeting
Cardiovascular and Cerebrovascular Comorbidities of Juvenile Dermatomyositis in United States Children
Jonathan I. Silverberg¹, Lauren Kwa², Michael C. Kwa², Anne Laumann² and Kaveh Ardalan^3,4, ¹Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune disease that causes vasculopathy and inflammation of skin and muscles. Previous studies in adult dermatomyositis suggest increased risks…
Abstract Number: 2961 • 2017 ACR/ARHP Annual Meeting
Body Composition and Myokine Levels in Juvenile Dermatomyositis and Associations with Physical Function
Birgit Nomeland Witczak¹, Kristin Godang², Jens Bollerslev^2,3, Thomas Schwartz^4,5, Berit Flatø^3,6, Ivar Sjaastad^3,4,7 and Helga Sanner^6,8, ¹Oslo University Hospital, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ³Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ⁴Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ⁷Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁸Norwegian National Advisory Unit on Rheumatic Diseases in Children and Adolescents, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway
Background/Purpose: JDM presents with proximal muscle weakness and atrophy is frequent. Still, body composition (BC) in JDM has not been widely studied, but is known…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].